1. Startpagina
  2. Nieuws en literatuur
  3. Diabetes

Linagliptine effectief en goed verdraagzaam i.c.m. metformine

Studieresultaten laten zien dat linagliptine een effectieve en goed verdraagzame toevoeging is aan metforminebehandeling voor verlaging van het  HbA1c bij patiënten met type 2 diabetes.

Linagliptin effective and well tolerated in combination with metformin
Nieuws - 16 sep. 2010

16 September 2010

Linagliptin  (Boehringer Ingelheim GmbH) is an effective and well-tolerated addition to metformin treatment for reducing glycated hemoglobin (HbA1c) in patients with Type 2 diabetes, show study findings.

Linagliptin is the latest oral antihyperglycemic drug to be developed in the dipeptidyl peptidase (DPP)-4 inhibitor class and has previously shown promise in early studies.

In this study, the researchers randomly assigned 333 patients with Type 2 diabetes and inadequate glycemic control (HbA1c 7.5-10.0%) to take placebo (n=71), open-label glimepiride 1-3 mg/day (n=65), or linagliptin 1, 5, or 10 mg/day (n= 65, 66, 66, respectively) for 12 weeks.The primary study outcome was reduction in HbA1c at study completion. The participants were aged 21-75 years and had a body mass index (BMI) of 25-40 kg/m2. All of the participants were also taking a standard dose of metformin.

The team reports that, compared with the placebo group, the linagliptin 1, 5, and 10 mg/day groups had significant reductions in HbA1c of 0.40%, 0.73%, and 0.67%, respectively, from baseline. In comparison, glimepiride produced a placebo-adjusted reduction in HbA1c of 0.90% from baseline. In addition, placebo-corrected mean reductions in fasting plasma glucose from baseline were 1.1, 1.9, and 1.6 mmol/l for the linagliptin 1, 5, and 10 mg/day groups, respectively.

Overall, 43.1% of the participants reported adverse events, but incidence was similar across all five groups. The most commonly reported events were nasopharyngitis, diarrhea, and nausea.Hypoglycemia was experienced by 5% of the patients taking glimepiride, but by none taking linagliptin or placebo.

"In this study, linagliptin as add-on to metformin resulted in a statistically significant and, more importantly, clinically relevant improvement in glycemic control in patients with Type 2 diabetes, without causing hypoglycemia," write the researchers in the journal Diabetic Medicine.

"A possible limitation of this study was the relatively short study duration and, thus, conclusions about longer-term efficacy and safety of linagliptin plus metformin must await the results of long-term trials that are currently ongoing," they add.

Registreren

We zijn blij te zien dat je geniet van CVGK…
maar wat dacht u van een meer gepersonaliseerde ervaring?

Registreer gratis